// App-Quantinova.ai

OR1‐005 : Obinutuzumab‐based induction and maintenance prolongs progression‐free survival in patients with previously untreated follicular lymphoma: primary results of the randomised phase 3 GALLIUM study

Researchers

Presenter

  • R Marcus

Principal Investigators

  • C Pocock

  • K Ando

  • W Klapper

  • S Opat

  • C Owen

  • E Phillips

  • R Sangha

  • R Schlag

  • J Seymour

  • W Townsend

  • M Trnen

  • M Wenger

  • G Fingerle-Rowson

  • K Rufibach

  • T Moore

  • M Herold

  • W Hiddemann

Medical Centers

  • Kings College Hospital, London,

  • Cancer Research UK Centre, University of Southampton,Southampton,Royaume-uni

  • East Kent Hospitals, Canterbury, United Kingdom

  • Tokai University School of Medicine, Isehara, Japan

  • University of Kiel, Kiel, Germany

  • Monash Health and Monash University, Melbourne, Australia

  • Foothills Medical Center and Tom Baker Cancer Centre, Calgary, Canada

  • Cancer Research UK & UCL Cancer Trials Centre, London, United Kingdom

  • Cross Cancer Institute, Edmonton, AB, Canada

  • Gemeinschaftspraxis Dr. Rudolf Schlag/Dr. Björn Schöttker, Würzburg, Germany

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Charles Univ and VFN, Prague, Czech Republic

  • Genentech Inc., San Francisco, United States

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • HELIOS‐Klinikum, Erfurt

  • Ludwig Maximilians University Munich, Munich, Germany

Locations

  • United Kingdom

  • Japan

  • Germany

  • Australia

  • Canada

  • Czech Republic

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • B-lymphocyte antigen CD20

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Bendamustine

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01332968

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved